Table 1 Characteristics at baseline (n (%))
Integrated treatmentc (n = 141) | Standard treatmentc (n = 135) | |
|---|---|---|
Age (years) | ||
18–29 | 14 (10) | 16 (12) |
30–39 | 41 (29) | 43 (32) |
40–49 | 44 (31) | 45 (33) |
≥ 50 | 42 (30) | 31 (23) |
Median (IQR) | 44 (36–52) | 42 (34–49) |
Sex | ||
Male | 103 (73) | 109 (81) |
Educational attainment | ||
Not completed primary school | 7 (5) | 12 (9) |
Completed primary school (9 years) | 67 (48) | 66 (49) |
Completed high school (12 years) | 52 (37) | 44 (31) |
Completed college or university | 13 (9) | 14 (10) |
Opioid agonist therapy | 120 (85) | 120 (88) |
Unstable housing past 30 daysa | 21 (14) | 18 (13) |
Injected drug use past 12 months | 81 (58) | 83 (64) |
Frequent drug use past 12 monthsb | ||
Alcohol | 35 (25) | 32 (25) |
Benzodiazepines | 55 (40) | 52 (41) |
Cannabis | 75 (54) | 72 (56) |
Opioids | 17 (12) | 15 (12) |
Stimulants (amphetamines and cocaine) | 48 (35) | 39 (30) |
Infectious diseases | ||
Hepatitis C virus genotypes | ||
1 | 47 (34) | 44 (33) |
2 | < 10 (1) | < 10 (4) |
3 | 91 (65) | 80 (61) |
4 | < 5 (0) | < 5 (1) |
6 | < 5 (0) | < 5 (1) |
Hepatitis B virus infection | 0 (0) | 0 (0) |
Human immunodeficiency virus | 0 (0) | < 5 (0) |
Liver stiffness | ||
Transient elastography (≥ 12.5 kPa) | 22 (16) | 14 (11) |
Aspartate transaminase to platelets ratio index (≥ 1.5) | 13 (10) | 13 (11) |